Log In
BCIQ
Print this Print this
 

Zylet, loteprednol etabonate/tobramycin

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionLoteprednol etabonate and tobramycin ophthalmic suspension
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationConjunctivitis
Indication DetailsTreat patients with steroid-responsive inflammatory ocular conditions who have or are at risk of developing superficial bacterial ocular infections
Regulatory Designation
PartnerPharmos Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/09/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today